HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Anesthesiology & Pain Medicine
RCT
Intranasal naloxone reverses opioid-induced respiratory depression in opioid-naive and daily users within 2 to 17 minutes
Narcan nasal spray reverses opioid breathing depression quickly
This prospective crossover trial enrolled 12 opioid-naive individuals and 18 daily opioid users.
Narcan nasal spray restored breathing within minutes in opioid users, but some had delayed or incomplete recovery.
May 1, 2026
Infectious Disease
Naloxone prescriptions from US retail pharmacies increased substantially from 2012 to 2018
Did naloxone access improve? Pharmacy prescriptions more than doubled in one year
An observational report of naloxone dispensing trends in US retail pharmacies found the number of prescriptions increased substantially from…
Naloxone prescriptions at U.S. retail pharmacies more than doubled from 2017 to 2018, showing a major jump in access to this life-saving ove…
CDC
Apr 6, 2026
Infectious Disease
Report describes overdose education and naloxone distribution programs in U.S. syringe service programs
How do syringe programs teach people to stop overdoses?
A report describes overdose education and naloxone distribution (OEND) programs within syringe service programs in the United States.
A new report looks at how syringe service programs across the U.S.
CDC
Apr 6, 2026